about
Immunochemical quantification of glycoconjugates in serum and cerebrospinal fluid of amyotrophic lateral sclerosis patientsNovel A18T and pA29S substitutions in α-synuclein may be associated with sporadic Parkinson's disease.Cerebellar ataxia with neuropathy and vestibular areflexia syndrome (CANVAS) - a case report and review of literature.Coprophenomena in Tourette syndrome.Association of ADORA1 rs2228079 and ADORA2A rs5751876 Polymorphisms with Gilles de la Tourette Syndrome in the Polish Population.Expression of RNAs Coding for Metal Transporters in Blood of Patients with Huntington's DiseaseTetrabenazine-induced oculogyric crisis - a rare complication in the treatment of Gilles de la Tourette syndrome.Effect of Riluzole on serum amino acids in patients with amyotrophic lateral sclerosis.Low frequency of the PARK2 gene mutations in Polish patients with the early-onset form of Parkinson disease.Coprolalia and copropraxia in patients with Gilles de la Tourette syndrome.Incidence of mutations in the PARK2, PINK1, PARK7 genes in Polish early-onset Parkinson disease patients.Aripiprazole in treatment of Gilles de la Tourette syndrome - New therapeutic option.Serum amino acid profile in patients with Parkinson's disease.Amino acids acting as transmitters in amyotrophic lateral sclerosis (ALS).Singular DYT6 phenotypes in association with new THAP1 frameshift mutationsSerum IgM anti-GM1 ganglioside antibodies in lower motor neuron syndromesErythropoietin concentration in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosisMatrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis
P50
Q28373690-A57F75BE-80F9-4C88-BF79-4FAB56408FB8Q30352615-B2B5847A-5882-4DE0-82FC-9DF4C510E0E2Q30872714-07E7DCAD-D148-4EAC-81A0-7B58C193D250Q34934096-258805B8-C9BB-4EF4-8C5C-1C61C9B0E0F2Q35759035-96131A1A-C6D4-48CC-A3D9-F708CB30BAC8Q36637306-E31BB8F3-461A-4B35-AD2F-15C6016FF96AQ38699112-30794075-BBBE-4BA6-9A87-754A35D7F4CCQ44029872-18313BC0-9728-4728-B4C0-25C2F8D62AACQ44457229-BA11F045-DCD3-4803-A9A9-7AA01217D3E7Q46902739-0EC7040E-FD72-4A3E-A317-D7E42B056E22Q47678707-885F7A4E-F6FC-4726-953E-E596F1DA1194Q47704082-307B8422-D6AE-4D31-B2C7-036C11B87E9CQ48043375-D69F733E-9FBE-42A3-9447-466C42235EAEQ48154923-C1BF913E-5D3D-4994-89D8-BAF4CA208C94Q59526235-6E4559A8-C928-433A-B585-037EF7B5D4E6Q75204416-151C9A57-E2C5-4ACD-8A18-2ACE7335E476Q82251921-B93BC737-BD70-477B-8751-0D813CFA7CD9Q84612193-E4AAA9B1-E103-4F24-A15B-C9D8CE191ED9
P50
description
researcher ORCID ID = 0000-0002-2701-191X
@en
wetenschapper
@nl
name
Piotr Janik
@ast
Piotr Janik
@en
Piotr Janik
@es
Piotr Janik
@nl
type
label
Piotr Janik
@ast
Piotr Janik
@en
Piotr Janik
@es
Piotr Janik
@nl
altLabel
Janik P
@en
prefLabel
Piotr Janik
@ast
Piotr Janik
@en
Piotr Janik
@es
Piotr Janik
@nl
P1053
M-5836-2018
P106
P1153
7005577198
P31
P496
0000-0002-2701-191X